Menopause and HRT: Implications of FDA's Labeling Update for Veozah
Thursday, 12 September 2024, 13:54
Significance of the FDA Update on Veozah
The FDA issued an important update, highlighting potential risks associated with Veozah in menopausal patients. This comes in response to a postmarketing report of acute mixed hepatocellular cholestatic liver injury. Such reports necessitate heightened awareness among healthcare providers.
Key Takeaways on Menopause and HRT
- Potential Risks: Understanding the implications of liver injury with hormone replacement therapies.
- Patient Education: Emphasizing the importance of discussing risks with patients considering HRT.
- Clinical Awareness: Obstetrics and gynecology professionals should monitor patients more closely.
For further information, please visit the official FDA announcements regarding Veozah.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.